Neurological disorders and therapeutics targeted to surmount the blood-brain barrier - Wikidata - wikimedia - TriplyDB

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

http://www.wikidata.org/entity/Q36119574

about

Nanoparticles for brain drug delivery Nanotechnology in neurology: Genesis, current status, and future prospects Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements Drug delivery systems, CNS protection, and the blood brain barrier Current approaches to enhance CNS delivery of drugs across the brain barriers Fabrication and Characterization of Gd-DTPA-Loaded Chitosan-Poly(Acrylic Acid) Nanoparticles for Magnetic Resonance Imaging.Bioactive marine drugs and marine biomaterials for brain diseases Nanoformulated cell-penetrating survivin mutant and its dual actions.Impaired mitochondrial energy production and ABC transporter function-A crucial interconnection in dementing proteopathies of the brain.The role of nanotechnology in control of human diseases: perspectives in ocular surface diseases.Dual agents loaded polymeric nanoparticle: Effect of process variables Transendothelial Transport and Its Role in Therapeutics.Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain.Polysorbate 80-coated PLGA nanoparticles improve the permeability of acetylpuerarin and enhance its brain-protective effects in rats.In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases.Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management

P2860

Q21285117-6EA94C6D-5A84-49DD-B21B-9D9869CA6E93 Q26771772-EE3F93C0-25D5-4776-B1C1-8AC7C6C38A69 Q26850868-A88E2761-6654-4AEB-A044-B40D9BC5870F Q30393215-E3132335-804F-47B8-BE27-7412B99D78E4 Q30432845-33BE3AEF-C62B-44E8-8AFE-A1EAE205B428 Q30437835-D5BBD810-797F-4DF8-908C-B51CAE4A858B Q30924405-442C7BF6-88CB-49BA-9919-1FAEDD56E0DD Q33736687-CA531F90-F63C-496E-A93D-FE5504DCAE61 Q33904982-A950DA8D-CD55-4205-BD53-1F7566C2E204 Q37351380-C2F51F7C-CBCC-424E-B072-121947AF7016 Q38550131-1C5A52FC-00AE-4A6D-828C-82C44BC016E6 Q38844946-A1F4EB6E-72BD-4411-8533-30F2FB5EAA4E Q38880426-424C91FA-8EF6-4349-BAF1-88142F49558C Q44610359-9BC612BA-62C1-4525-98A5-586410D6DDA3 Q52148832-3B47B746-D4F0-48C0-96EE-7B4687D7F92F Q53697270-D5FA067F-BF50-45D5-B13C-A1D20843156A Q57169956-2A276C50-881B-4473-AF23-5CFDCE9AF9D2

P2860

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

http://www.wikidata.org/entity/Q36119574

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

@ast

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

@en

type

label

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

@ast

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

@en

prefLabel

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

@ast

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

@en

P1433

Q36119574-25BFF7CD-59D2-490F-9AA1-7598167454C8

P1476

Q36119574-B94B7C01-9DD2-42E4-A0DA-6FF0FB53B277

P2093

Q36119574-1689AA74-9F2B-458A-A987-E78B2E73C088

Q36119574-81072F39-FCBB-4529-9C42-3E573AF61EE0

P2860

Q36119574-009874D8-3548-43D1-93BB-A05CB2F68288

Q36119574-011AF1B0-AE16-4134-88D5-168D1E8DD82F

Q36119574-01B46E5B-A4D7-4D92-8758-AB6EA6459DF2

Q36119574-0261D509-20CA-4A49-9C1B-30020EF026F3

Q36119574-033CDAAA-7C2D-4AB0-AAAF-2D4EC428C1EE

Q36119574-04541A50-92F8-4915-A1A6-26235F1070A4

Q36119574-067747EC-CD48-4DB3-9D17-C24B31C8F9E4

Q36119574-0679E1F5-0197-4855-9307-7CC2BCD031B4

Q36119574-076DEA7F-B721-4809-97FE-89A4281A5275

Q36119574-079FDC0E-8161-4723-BC36-E9999A2212AB

P304

Q36119574-3DC7EC45-47CA-4BCF-94DE-C545A7887CD3

P31

Q36119574-2C290A64-3C7E-43B9-BD87-C62802D46F95

Q36119574-BBB1D07E-7B8E-4CEE-9043-D07FB1A9D31A

P356

Q36119574-2AD463E0-F681-4953-AD85-BDD55F4E5511

P407

Q36119574-CB13F1EE-D126-46F0-93C2-2D2996DF4F79

P478

Q36119574-5591E4CC-298F-44E7-9535-83E82ADABA73

P50

Q36119574-512CF245-E555-4B35-8582-71FF57C7E28A

P577

Q36119574-C76C2ACB-039F-4F8C-B884-E97AB7AD753D

P5875

Q36119574-2AB290B3-01C0-40E6-8C81-1C2B5C657A5A

P698

Q36119574-EFE0FC63-A122-42E8-B79E-D03F829D6649

P921

Q36119574-243E3E8B-F6E2-4A32-BA8A-374B28ADB23B

Q36119574-565E515C-3777-462A-82BC-F620819D6B5F

Q36119574-682751B5-97A2-4754-9EC3-5D70A05D7B02

Q36119574-EAF2FA37-81FF-49C2-A04A-D552F030C9F2

Q36119574-EFA83087-7482-43D6-9CC6-D2D3F1122A22

Q36119574-F5773793-BEFC-4AC7-A31B-6E7DCF41BB2D

P932

Q36119574-6C7B9117-009D-4610-A273-968178B8B913

P356

P1433

International Journal of Nanomedicine

P1476

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier

@en

P2093

Bhasker Sriramoju

http://www.w3.org/2001/XMLSchema#string

Rupinder K Kanwar

http://www.w3.org/2001/XMLSchema#string

P2860

Hereditary early-onset Parkinson's disease caused by mutations in PINK1

Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36.

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

Drug delivery and nanoparticles:applications and hazards

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer

Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

P304

3259-3278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IJN.S30919

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230589773

http://www.w3.org/2001/XMLSchema#string

P698

22848160

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

blood–brain barrier

neurological disorder

manufactured product

pharmaceutical preparation

P932

3405884

http://www.w3.org/2001/XMLSchema#string